Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Inc. (ABBV)
Price$257.12Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | $18.79B | $18.38B | $17.44B |
| Gross profit | $42.96B | $39.43B | $33.90B | $40.64B | $38.75B | $30.42B | $25.83B | $25.04B | $21.17B | $19.81B | $18.36B | $15.53B | $14.21B | $13.87B | $12.80B |
| Gross margin | 70.24% | 69.99% | 62.42% | 70.00% | 68.96% | 66.41% | 77.64% | 76.44% | 75.04% | 77.25% | 80.31% | 77.83% | 75.62% | 75.47% | 73.41% |
| Research & development | $9.10B | $12.79B | $7.67B | $6.51B | $6.92B | $6.38B | $6.41B | $10.33B | $5.01B | $4.38B | $4.29B | $3.30B | $2.85B | $2.78B | $2.62B |
| Operating expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B | $18.67B | $16.30B | $15.32B | $16.55B | $13.13B | $12.56B | $13.82B |
| Operating income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B | $7.54B | $3.41B | $5.66B | $5.82B | $3.62B |
| Operating margin | 24.65% | 16.22% | 23.49% | 31.21% | 31.89% | 24.81% | 39.03% | 19.49% | 33.83% | 36.43% | 32.97% | 17.09% | 30.14% | 31.65% | 20.75% |
| EBITDA | $23.21B | $17.52B | $21.45B | $26.58B | $26.45B | $17.83B | $15.00B | $8.15B | $11.05B | $10.53B | $8.37B | $4.20B | $6.56B | $6.97B | $4.89B |
| EBITDA margin | 37.96% | 31.11% | 39.50% | 45.79% | 47.06% | 38.94% | 45.09% | 24.88% | 39.15% | 41.07% | 36.63% | 21.03% | 34.92% | 37.91% | 28.04% |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | — | — | — |
| Net profit margin | 6.91% | 7.59% | 8.95% | 20.39% | 20.54% | 10.08% | 23.69% | 17.36% | 18.82% | 23.22% | 22.50% | 8.89% | — | — | — |
| Basic EPSper basic share | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 | $3.31 | $3.65 | $3.15 | $1.11 | $2.58 | $3.35 | $2.18 |
| Diluted EPSper diluted share | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | $2.56 | $3.35 | $2.18 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 4, 2026Form 4 | Purdue David RyanSVP, Controller | SellCommon Stock, $0.01 par value | 5.2K | $233.56 | $1.22M | 2.7K |
| Mar 2, 2026Form 4 · 10b5-1 | Siatis Perry CEVP, GC AND SECRETARY | SellCommon Stock, $0.01 par value | 2.6K | $235.26 | $611.7K | 4.6K |
| Mar 2, 2026Form 4 · 10b5-1 | Siatis Perry CEVP, GC AND SECRETARY | SellCommon Stock, $0.01 par value | 10.3K | $234.66 | $2.41M | 7.2K |
| Mar 2, 2026Form 4 · 10b5-1 | Siatis Perry CEVP, GC AND SECRETARY | SellCommon Stock, $0.01 par value | 5.8K | $233.51 | $1.35M | 17.5K |
| Feb 25, 2026Form 4 · 10b5-1 | Siatis Perry CEVP, GC AND SECRETARY | SellCommon Stock, $0.01 par value | 22.4K | $230.00 | $5.15M | 38.1K |
Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...